CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Duloxetine +1 moredrug
Likely dose
Duloxetine 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02535000
NCT02535000Phase 4Completed
CompareCT.gov

Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery

Serviço de Anestesiologia de Joinville·interventional·Posted Aug 28, 2015·Updated Oct 9, 2020

In Brief

A Phase 4 clinical trial evaluating Duloxetine and Placebo for Intervertebral Disc Degeneration. Completed, enrolled 60 participants.

Detailed Summary

Duloxetine as an analgesic agent in patients undergoing elective spine surgery: evaluation with fentanyl demand controlled by the patient. The primary objective is to evaluate the efficacy of duloxetine in fentanyl consumption during the postoperative period of patients undergoing elective spine surgery by intervertebral disc degeneration . Secondary endpoints were pain scores and the presence or absence of adverse effects such as headache, nausea, vomiting, itching, dizziness and drowsiness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntervertebral Disc Degeneration
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 28, 2015
Enrollment StartJan 1, 2014
Primary CompletionOct 20, 2015
Study CompletionOct 30, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.8 years ago

Interventions

Duloxetinedrug

duloxetine 60 mg

Placebodrug

placebo